Niteesh K Choudhry1, Thomas Isaac2, Julie C Lauffenburger3, Chandrasekar Gopalakrishnan4, Nazleen F Khan4, Marianne Lee2, Amy Vachon2, Tanya L Iliadis2, Whitney Hollands2, Scott Doheny2, Sandra Elman2, Jacqueline M Kraft2, Samrah Naseem2, Joshua J Gagne4, Cynthia A Jackevicius5, Michael A Fischer4, Daniel H Solomon6, Thomas D Sequist7. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Center for Healthcare Delivery Sciences (C4HDS), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: nkchoudhry@bwh.harvard.edu. 2. Atrius Health, Newton, MA, USA. 3. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Center for Healthcare Delivery Sciences (C4HDS), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 5. Western University of Health Sciences, Pomona, CA; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 6. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 7. Division of General Internal Medicine and Department of Health Care Policy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Approximately half of patients with chronic cardiometabolic conditions are nonadherent with their prescribed medications. Interventions to improve adherence have been only modestly effective because they often address single barriers to adherence, intervene at single points in time, or are imprecisely targeted to patients who may not need adherence assistance. OBJECTIVE: To evaluate the effect of a multicomponent, behaviorally tailored pharmacist-based intervention to improve adherence to medications for diabetes, hypertension, and hyperlipidemia. TRIAL DESIGN: The STIC2IT trial is a cluster-randomized pragmatic trial testing the impact of a pharmacist-led multicomponent intervention that uses behavioral interviewing, text messaging, mailed progress reports, and video visits. Targeted patients are those who are nonadherent to glucose-lowering, antihypertensive, or statin medications and who also have evidence of poor disease control. The intervention is tailored to patients' individual health barriers and their level of health activation. We cluster-randomized 14 practice sites of a large multispecialty group practice to receive either the pharmacist-based intervention or usual care. STIC2IT has enrolled 4,076 patients who will be followed up for 12months after randomization. The trial's primary outcome is medication adherence, assessed using pharmacy claims data. Secondary outcomes are disease control and health care resource utilization. CONCLUSION: This trial will determine whether a technologically enabled, behaviorally targeted pharmacist-based intervention results in improved adherence and disease control. If effective, this strategy could be a scalable method of offering tailored adherence support to those with the greatest clinical need.
RCT Entities:
BACKGROUND: Approximately half of patients with chronic cardiometabolic conditions are nonadherent with their prescribed medications. Interventions to improve adherence have been only modestly effective because they often address single barriers to adherence, intervene at single points in time, or are imprecisely targeted to patients who may not need adherence assistance. OBJECTIVE: To evaluate the effect of a multicomponent, behaviorally tailored pharmacist-based intervention to improve adherence to medications for diabetes, hypertension, and hyperlipidemia. TRIAL DESIGN: The STIC2IT trial is a cluster-randomized pragmatic trial testing the impact of a pharmacist-led multicomponent intervention that uses behavioral interviewing, text messaging, mailed progress reports, and video visits. Targeted patients are those who are nonadherent to glucose-lowering, antihypertensive, or statin medications and who also have evidence of poor disease control. The intervention is tailored to patients' individual health barriers and their level of health activation. We cluster-randomized 14 practice sites of a large multispecialty group practice to receive either the pharmacist-based intervention or usual care. STIC2IT has enrolled 4,076 patients who will be followed up for 12months after randomization. The trial's primary outcome is medication adherence, assessed using pharmacy claims data. Secondary outcomes are disease control and health care resource utilization. CONCLUSION: This trial will determine whether a technologically enabled, behaviorally targeted pharmacist-based intervention results in improved adherence and disease control. If effective, this strategy could be a scalable method of offering tailored adherence support to those with the greatest clinical need.
Authors: Richard A Hansen; Mimi M Kim; Liping Song; Wanzhu Tu; Jingwei Wu; Michael D Murray Journal: Ann Pharmacother Date: 2009-03-03 Impact factor: 3.154
Authors: Julie C Lauffenburger; Akhila Balasubramanian; Joel F Farley; Cathy W Critchlow; Cynthia D O'Malley; Mary T Roth; Virginia Pate; M Alan Brookhart Journal: Pharmacoepidemiol Drug Saf Date: 2013-05-21 Impact factor: 2.890
Authors: Julie A Schmittdiel; Gregory A Nichols; Wendy Dyer; John F Steiner; Andrew J Karter; Marsha A Raebel Journal: Med Care Date: 2015-04 Impact factor: 2.983
Authors: Ira B Wilson; Floyd J Fowler; Carol A Cosenza; Joanne Michaud; Judy Bentkover; Aadia Rana; Laura Kogelman; William H Rogers Journal: AIDS Behav Date: 2014-12
Authors: Julie C Lauffenburger; Thomas Isaac; Romit Bhattacharya; Thomas D Sequist; Chandrasekar Gopalakrishnan; Niteesh K Choudhry Journal: Am J Cardiol Date: 2019-11-07 Impact factor: 2.778
Authors: Niteesh K Choudhry; Alexis A Krumme; Patrick M Ercole; Charmaine Girdish; Angela Y Tong; Nazleen F Khan; Troyen A Brennan; Olga S Matlin; William H Shrank; Jessica M Franklin Journal: JAMA Intern Med Date: 2017-05-01 Impact factor: 21.873
Authors: Constance P Fontanet; Niteesh K Choudhry; Thomas Isaac; Thomas D Sequist; Chandrasekar Gopalakrishnan; Joshua J Gagne; Cynthia A Jackevicius; Michael A Fischer; Daniel H Solomon; Julie C Lauffenburger Journal: Health Serv Res Date: 2021-08-13 Impact factor: 3.734
Authors: Niteesh K Choudhry; Thomas Isaac; Julie C Lauffenburger; Chandrasekar Gopalakrishnan; Marianne Lee; Amy Vachon; Tanya L Iliadis; Whitney Hollands; Sandra Elman; Jacqueline M Kraft; Samrah Naseem; Scott Doheny; Jessica Lee; Julie Barberio; Lajja Patel; Nazleen F Khan; Joshua J Gagne; Cynthia A Jackevicius; Michael A Fischer; Daniel H Solomon; Thomas D Sequist Journal: JAMA Intern Med Date: 2018-09-01 Impact factor: 21.873
Authors: Jennifer Lewey; Wenhui Wei; Julie C Lauffenburger; Sagar Makanji; Alan Chant; Jeff DiGeronimo; Gina Nanchanatt; Saira Jan; Niteesh K Choudhry Journal: BMJ Open Date: 2017-10-30 Impact factor: 2.692